Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 09:05 pm
Share
Y-mAbs Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 20.45 million compared to USD 12.54 million a year ago. Net loss was USD 7.75 million compared to USD 27.53 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.63 a year ago.
For the nine months, revenue was USD 61.46 million compared to USD 33.82 million a year ago. Net loss was USD 20.44 million compared to USD 96.73 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 2.21 a year ago.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Y-MABS THERAPEUTICS, INC. 
